Canada Approves Pfizer’s RSV Vaccine
The vaccine was approved for older adults and infants through maternal immunization.
The vaccine was approved for older adults and infants through maternal immunization.
The vaccine builds on the company's previously approved vaccine by including seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.
The FDA approved the Pfizer/BioNTech SARS-CoV-2 vaccine (Comirnaty) for active immunization to prevent COVID-19 in individuals 12 through 15 years of age.
Pfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.
Read MorePfizer and BioNTech have requested FDA authorization of a second booster dose of their COVID-19 vaccine for adults 65 years of age and older.
Read MoreA nationwide study from the U.S. Centers for Disease Control and Prevention shows that immunity against severe COVID-19 disease begins to wane four months after receipt of the third dose of an mRNA vaccine.
Read MoreThe FDA has postponed a Feb 15 meeting of its Vaccines and Related Biological Products Advisory Committee that was intended to discuss emergency use authorization of a two-dose regimen of the Pfizer-BioNTech vaccine for children age 6-months through 4-years-old.
Read MorePfizer and BioNTech have submitted an application for emergency authorization of its COVID-19 vaccine in children age 6 months through 4 years old.
Read MoreThe Pfizer and BioNTech COVID-19 vaccine is the first to be FDA-authorized as a booster for adolescents 12 through 15 years of age in the US.
Read MoreThe US FDA has authorized the emergency use of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients age 12 and older.
Read MoreAccording to data, Pfizer’s COVID-19 antiviral Paxlovid reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) with no patient deaths.
Read MoreVaccines conferred protection from all COVID-19 variants but there was reduced antibody neutralization of both the Beta and Delta variants.
Read MoreExperts say the success of COVID Antiviral Pills depends on whether high-risk patients will be able to get tested, and then treated, fast enough to make a difference.
Read MoreThe FDA expanded emergency use for both the Moderna and Pfizer-BioNTech COVID-19 vaccine boosters for all individuals 18 years of age and older.
Read MorePfizer says its antiviral pill Paxlovid reduced the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19.
Read More